NetworkNewsBreaks – Coherus BioSciences, Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report
Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Coherus announced that toripalimab (tori) in combination with chemo significantly prolonged PFS and OS in patients with advanced esophageal squamous cell carcinoma (‘ESCC’), compared w/ chemo alone. Despite the press release not containing numbers, we had a look at the benchmark data for anti-PD1s in combo w/ chemo being studied in this indication, as well as its potential market size, to start to do work around it. Overall, an incremental win for Coherus as the Junshi thesis…







